375 related articles for article (PubMed ID: 29471933)
1. Safety and Effectiveness of Second-Generation Drug-Eluting Stents in Patients With Left Main Coronary Artery Disease.
Lee PH; Kwon O; Ahn JM; Lee CH; Kang DY; Lee JB; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ
J Am Coll Cardiol; 2018 Feb; 71(8):832-841. PubMed ID: 29471933
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of different contemporary drug-eluting stents in routine clinical practice: a multigroup propensity score analysis using data from the stent-specific, multicenter, prospective registries.
Kwon O; Kang SH; Lee JB; Ahn JM; Lee CH; Kang DY; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ;
Coron Artery Dis; 2019 Jun; 30(4):255-262. PubMed ID: 30883430
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of contemporary drug-eluting stents in patients with and without diabetes mellitus: Multigroup propensity-score analysis using data from stent-specific, multicenter, prospective registries.
Kwon O; Lee JB; Ahn JM; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ;
Catheter Cardiovasc Interv; 2020 Aug; 96(2):243-252. PubMed ID: 31478593
[TBL] [Abstract][Full Text] [Related]
4. Differential cutoff points and clinical impact of stent parameters of various drug-eluting stents for predicting major adverse clinical events: An individual patient data pooled analysis of seven stent-specific registries and 17,068 patients.
Lee CH; Kang DY; Han M; Hur SH; Rha SW; Her SH; Seung KB; Kim KS; Lee PH; Ahn JM; Lee SW; Park SW; Park DW; Park SJ;
Int J Cardiol; 2019 May; 282():17-23. PubMed ID: 30745256
[TBL] [Abstract][Full Text] [Related]
5. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen), a randomized, controlled, noninferiority trial.
Park KW; Kang SH; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Hur SH; Ryu JK; Lee BR; Park YW; Chae IH; Kim HS;
J Am Coll Cardiol; 2014 Jul; 63(25 Pt A):2805-16. PubMed ID: 24814486
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW
J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Contemporary Drug-Eluting Stents in Patients Undergoing Complex High-Risk Indicated Procedures.
Jeong YJ; Hyun J; Lee J; Kim JH; Yang Y; Choe K; Lee JS; Park H; Cho SC; Kang DY; Lee PH; Ahn JM; Park DW; Park SJ;
JACC Asia; 2022 Apr; 2(2):182-193. PubMed ID: 36339122
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Safety and Efficacy of Platinum Chromium Everolimus-Eluting Stents in Coronary Artery Disease: 5-Year Results From the PLATINUM Trial.
Kelly CR; Teirstein PS; Meredith IT; Farah B; Dubois CL; Feldman RL; Dens J; Hagiwara N; Rabinowitz A; Carrié D; Pompili V; Bouchard A; Saito S; Allocco DJ; Dawkins KD; Stone GW
JACC Cardiovasc Interv; 2017 Dec; 10(23):2392-2400. PubMed ID: 29217001
[TBL] [Abstract][Full Text] [Related]
9. Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries).
Lee JM; Park KW; Han JK; Yang HM; Kang HJ; Koo BK; Bae JW; Woo SI; Park JS; Jin DK; Jeon DW; Oh SK; Park JS; Kim DI; Hyon MS; Jeon HK; Lim DS; Kim MG; Rha SW; Her SH; Hwang JY; Kim S; Choi YJ; Kang JH; Moon KW; Jang Y; Kim HS
Am J Cardiol; 2014 Nov; 114(9):1329-38. PubMed ID: 25217457
[TBL] [Abstract][Full Text] [Related]
10. Comparison of biolimus A9-eluting (Nobori) and everolimus-eluting (Promus Element) stents in patients with de novo native long coronary artery lesions: a randomized Long Drug-Eluting Stent V trial.
Lee JY; Park DW; Kim YH; Ahn JM; Kim WJ; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Yang TH; Lee BK; Lee NH; Yang JY; Shin WY; Park HS; Kim KS; Hur SH; Lee SY; Park JS; Choi YS; Lee SU; Her SH; Park SJ
Circ Cardiovasc Interv; 2014 Jun; 7(3):322-9. PubMed ID: 24823426
[TBL] [Abstract][Full Text] [Related]
11. Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials.
Kang SH; Chae IH; Park JJ; Lee HS; Kang DY; Hwang SS; Youn TJ; Kim HS
JACC Cardiovasc Interv; 2016 Jun; 9(12):1203-1212. PubMed ID: 27262860
[TBL] [Abstract][Full Text] [Related]
12. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
[TBL] [Abstract][Full Text] [Related]
13. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
[TBL] [Abstract][Full Text] [Related]
14. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
[TBL] [Abstract][Full Text] [Related]
15. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
[TBL] [Abstract][Full Text] [Related]
16. Two-year clinical outcomes of zotarolimus- and everolimus-eluting durable-polymer-coated stents versus biolimus-eluting biodegradable-polymer-coated stent in patients with acute myocardial infarction with dyslipidemia after percutaneous coronary intervention: data from the KAMIR.
Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
Heart Vessels; 2019 Feb; 34(2):237-250. PubMed ID: 30167772
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Different Types of Drug-Eluting Stents for De Novo Long Coronary Artery Lesions.
Kang DY; Jang JS; Chang M; Lee CH; Lee PH; Ahn JM; Lee SW; Kim YH; Park SW; Park DW; Park SJ;
JACC Asia; 2022 Aug; 2(4):446-456. PubMed ID: 36339368
[TBL] [Abstract][Full Text] [Related]
18. Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.
van der Heijden LC; Kok MM; Lam MK; Danse PW; Schramm AR; Jessurun GA; Tjon Joe Gin RM; van Houwelingen KG; Hautvast RW; Linssen GC; Sen H; Löwik MM; IJzerman MJ; Doggen CJ; von Birgelen C
Clin Res Cardiol; 2016 Mar; 105(3):206-15. PubMed ID: 26329584
[TBL] [Abstract][Full Text] [Related]
19. Impact of stent designs of second-generation drug-eluting stents on long-term outcomes in coronary bifurcation lesions.
Jang WJ; Chun WJ; Park IH; Choi KH; Song YB; Koo BK; Doh JH; Hong SJ; Nam CW; Gwon HC
Catheter Cardiovasc Interv; 2021 Sep; 98(3):458-467. PubMed ID: 32729655
[TBL] [Abstract][Full Text] [Related]
20. Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).
Sen H; Lam MK; Löwik MM; Danse PW; Jessurun GA; van Houwelingen KG; Anthonio RL; Tjon Joe Gin RM; Hautvast RW; Louwerenburg JH; de Man FH; Stoel MG; van der Heijden LC; Linssen GC; IJzerman MJ; Tandjung K; Doggen CJ; von Birgelen C
JACC Cardiovasc Interv; 2015 Jun; 8(7):889-99. PubMed ID: 26003019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
